Sanofi - American Depositary Shares (NQ:SNY)

39.92 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

42 43 Next >

FDA Approves Sanofi's Hemophilia Drug ↗

March 31, 2025

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with as few as six injections per year.

Via Benzinga

Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)

March 28, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Don't overlook SANOFI-ADR (NASDAQ:SNY)—it's a hidden gem with strong fundamentals and an attractive price tag. ↗

March 26, 2025

Discover SANOFI-ADR, an undervalued stock. NASDAQ:SNY showcases solid financial health and profitability while maintaining an appealing valuation.

Via Chartmill

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Is NASDAQ:SNY suited for dividend investing? ↗

February 26, 2025

Is SANOFI-ADR (NASDAQ:SNY) suited for dividend investing?

Via Chartmill

How Is The Market Feeling About Sanofi? ↗

February 14, 2025

Via Benzinga

This ACNB Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday ↗

March 21, 2025

Via Benzinga

Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal ↗

March 20, 2025

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with a promising bispecific antibody.

Via Benzinga

Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. ↗

March 20, 2025

Why SANOFI-ADR (NASDAQ:SNY) qualifies as a good dividend investing stock.

Via Chartmill

FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva ↗

March 18, 2025

Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.

Via Benzinga

Sanofi Stock Forms Golden Cross As Dupixent Eyes FDA Green Light: Can The Bullish Run Continue? ↗

March 12, 2025

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Via Benzinga

Merck Injects $1 Billion To Expand Vaccine Production In US ↗

March 11, 2025

Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments.

Via Benzinga

Top 3 Health Care Stocks That May Keep You Up At Night In Q1 ↗

March 11, 2025

Via Benzinga

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD

March 08, 2025

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients ↗

March 07, 2025

Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years.

Via Benzinga

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

For those who appreciate value investing, SANOFI-ADR (NASDAQ:SNY) is a compelling option with its solid fundamentals. ↗

March 03, 2025

When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Is SANOFI-ADR (NASDAQ:SNY) Ready to Break Out of Its Range? ↗

February 28, 2025

Investors are keeping a close eye on SANOFI-ADR (NASDAQ:SNY) as it boasts an impressive technical rating of 8 out of 10, signaling a possible breakout.

Via Chartmill

Novavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi Partnership ↗

February 27, 2025

The company expects to generate $300 million to $350 million in adjusted licensing, royalties, and other revenue in 2025.

Via Stocktwits

Moderna Tumbles As RFK Jr. Reportedly Mulls Pulling $590 Million In Bird Flu Funds ↗

February 27, 2025

Moderna is under pressure as two of its vaccines hit potential snags.

Via Investor's Business Daily

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value ↗

February 27, 2025

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.

Via Benzinga

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

February 27, 2025

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Via MarketBeat

Novavax Retail Traders Stay Bullish Ahead Of Q4 Print Even As RFK Jr's HHS Leadership Causes Ripples ↗

February 27, 2025

Kennedy, a longtime vaccine skeptic, now oversees HHS decisions that could impact vaccine makers, making his leadership a wild card for Novavax.

Via Stocktwits

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease ↗

February 24, 2025

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Via Benzinga

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

February 22, 2025

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes ↗

February 18, 2025

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Via Benzinga

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study ↗

February 13, 2025

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by €0.15 following a $250M charge.

Via Benzinga

Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains. ↗

February 06, 2025

The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.

Via Investor's Business Daily

Why Regeneron Pharmaceuticals Stock Topped the Market on Tuesday ↗

February 04, 2025

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.